Skip to content
Public Health · Article 32

Supreme Court Directs Centre to Constitute Committee on Unethical Pharmaceutical Marketing: Recommendations on Statutory Framework for UCPMP Within Two Months of First Meeting

UCPMP 2024Article 32Article 142Right to HealthPharma MarketingSeparation of Powers

In Federation of Medical and Sales Representatives Association of India & Ors. v. Union of India & Ors., 2026 INSC 1097, the Supreme Court, hearing a public interest writ petition against unethical pharmaceutical marketing such as gifts, hospitality, sponsored travel and monetary benefits to doctors, directed the Union of India to constitute an expert Committee within two weeks. The Committee will examine the adequacy of the current framework, including the voluntary UCPMP 2024, and recommend a regulatory or statutory framework within two months of its first meeting. Respecting the separation of powers, the Court declined to frame policy itself but ensured a meaningful consultative process.

Key Takeaways

  • Doctors are bound by the 2002 IMC Regulations, but pharma companies face only a voluntary code.
  • Petitioners linked unethical marketing to irrational prescribing, costly brands, adverse reactions and antimicrobial resistance, engaging the right to health under Article 21.
  • A 2022 NITI Aayog committee produced no outcome; the Union proposed a three-member committee in 2026.
  • The Committee must examine monitoring, enforcement and transparency, hear petitioners and stakeholders, and may take expert help.
  • Recommendations are due within two months of the first meeting, followed by a reasoned decision by the Union.
  • The Court will not formulate policy, consistent with the separation of powers.

Case Details at a Glance

Case titleFederation of Medical and Sales Representatives Association of India & Ors. v. Union of India & Ors.
Citation2026 INSC 1097
Case numberWrit Petition (Civil) No. 323 of 2021
BenchJustice Vikram Nath and Justice Sandeep Mehta
Authored byJustice Sandeep Mehta
Date of order8 October 2026
Next listing29 January 2027 (part-heard)
ResultDirections to constitute Committee; matter pending

Facts of the Case

The petition, filed in 2021 under Article 32, sought statutory backing for the code on pharmaceutical marketing or guidelines under Articles 32, 141, 142 and 144. Notice issued on 11 March 2022. After a 2022 high-level committee bore no result, the Court gave the Union a last opportunity in July 2026. The Union then reported meetings of Secretaries and with industry bodies and proposed a committee, with UCPMP 2024 governing meanwhile. The petitioners did not object but sought a consultative process.

Issues Before the Supreme Court

  1. Should the Court direct a time-bound process to frame a regulatory framework for pharmaceutical marketing?

Directions issued

Under Articles 32 and 142, the Court directed: (A) a committee within two weeks; (B) a holistic examination of the framework, monitoring, enforcement and transparency; (C) consideration of material from petitioners and intervenors, and hearing stakeholders; (D) recommendations on a regulatory or statutory framework; (E) liberty to take expert help; (F) recommendations within two months of the first meeting; and (G) a reasoned decision by the Union at the earliest. A compliance affidavit is to follow.

Separation of powers

The Court emphasised that policy is for the executive, but that it can facilitate a meaningful, time-bound process where fundamental rights such as health are engaged.

Final Decision

Directions issued. The Union must constitute the Committee and act on its recommendations. The matter is part-heard and listed on 29 January 2027.

Analysis and Practical Points

What this means:

  • Pharma companies: expect stricter, possibly statutory, rules on gifts, travel, sponsorships and samples, with enforcement and disclosure.
  • Doctors: existing obligations under the 2002 Regulations remain.
  • Public health groups: can place material before the Committee.

Frequently Asked Questions

What did the Supreme Court order on pharma marketing?

A committee within two weeks to recommend a regulatory or statutory framework within two months of its first meeting.

Is UCPMP 2024 binding?

It currently operates as a code; the petition seeks statutory backing, which the Committee will consider.

Why did the Court not frame rules itself?

Because of the separation of powers; it facilitated the process instead.

Which fundamental right is involved?

The right to health under Article 21.

When is the next hearing?

29 January 2027.

This article is for general information only and does not constitute legal advice. Readers should refer to the certified copy of the judgment and consult a qualified professional before acting. See our Editorial Policy and Disclaimer.